Loading clinical trials...

Hair Growth Efficacy and Safety of NGF-574H in Adult With Androgenic Alopecia | Clinical Trials | Clareo Health

COMPLETEDNA

Hair Growth Efficacy and Safety of NGF-574H in Adult With Androgenic Alopecia

Clinical Study for the Assessment of the Hair Growth Efficacy and Safety of a Cosmetic Investigational Product, After Repeated Applications for 24 Weeks, Under Normal Conditions of Use, in the Asian Adult Subjects With Androgenic Alopecia

NCT03676400•Medipost Co Ltd.

View on ClinicalTrials.gov

Summary

The purpose of this study is to assess whether cosmetic investigational product containing NGF-574H is safe and effective in the treatment of androgenic alopecia in asian adults.

Detailed Description

NGF-574H is a obtained by collection of paracrine factors secreted by human umbilical cord blood-derived mesenchymal stem cell that was exposed in vitro to an artificially designed environment mimicking alopecia state in hair follicles to prime the composition of the paracrine factors optimized for hair growth. This study is to assess and confirm whether NGF-574H is safe and effective in the treatment of androgenic alopecia in asian adults.

Eligibility

Age

18 - 60 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Origin: Asian (Korean)
•2. Age: adult from 18 to 60 years old
•3. Sex: female (minimum 70) and male
•4. Understanding of the language spoken in the research center: subjects able to read the documents they are presented with and to hold to what they are explained.
•5. Social cover: subjects having medical coverage
•6. Subjects whose state of health, at the moment of inclusion, (auto-questionnaires and medical examinations for the recruitment, selection and inclusion), are compatible with this type of study.
•7. Subjects can be pursuit and observation during the study period.
•8. Subjects have a "hair loss grade" as below criteria:
•* BASP grade: Basic type (M2 to M3, or C2 to C3, or U1 to U3) or Specific type (V1 to V3, or F1 to F3)
•* For female: Ludwig grade: Ⅰ to Ⅱ
+9 more criteria

Exclusion Criteria

•1. Subject deprived from liberty by a judiciary or administrative decision, sick subject in situation of emergency.
•2. Under age or off age subject protected by law, as well as those admitted to sanitary or social facilities, ever since the research can be performed in another manner.
•3. Subject who cannot be contacted in case of emergency.
•4. Females in pregnancy (positive urine pregnancy-tests performed at screening(visit 1 and visit 9)or nursing or without effective contraception method.
•5. Subject with any systemic disorder or skin disease (e.g. scalp disorders such as seborrheic dermatitis or scalp psoriasis) or presenting genetic or hormonal alopecia.
•6. Subject with a condition or receiving a medication which, in the opinion of the investigator, could compromise the safety of the subject or affect the outcome of the study.
•7. Subject using topic cosmetic treatment or oral nutritional supplement likely to interfere on hair loss parameters during the last 3 months prior to the start of the study (screening)
•8. Subject having a medical treatment likely to induce an alopecia or hypertrichosia, or having stopped it from than 3 months (including prostaglandins, rubefacients agents, all vasodilators, anti-androgens, all local hormonal treatment, etc...)
•9. Subject following a long period (\>30 days) treatment of anti-inflammatory during the last 4 months before the start of the study (screening)
•10. Subject following a short period (\<30 days) treatment of anti-inflammatory stopped or ongoing preceding the screening period.
+3 more criteria

Locations (1)

Dankook University Hospital

Cheonan, Chung Nam, South Korea

Key Dates

Start Date

October 2, 2018

Primary Completion Date

July 22, 2019

Completion Date

July 24, 2019

Last Updated

August 12, 2019

Enrollment

ACTUAL participants

Conditions

Androgenic Alopecia

Interventions

conditioned media of umbilical cord blood-derived stem cells

OTHER

Placebo

OTHER

Androgenic Alopecia TH07 Clinical Trial

NCT07435012

Androgenic Alopecia

View study

RECRUITINGNA

Autologous Hair Follicle Secretome for Androgenic Alopecia (Single Site)

NCT07107841

Androgenic AlopeciaAlopecia+1 more

View study

NOT_YET_RECRUITINGEARLY_PHASE1

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 12, 2019Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Hair Growth Efficacy and Safety of NGF-574H in Adult With Androgenic Alopecia

Inclusion Criteria

Exclusion Criteria

Androgenic Alopecia TH07 Clinical Trial

Autologous Hair Follicle Secretome for Androgenic Alopecia (Single Site)

Evaluating the Efficacy of Platelet-rich Plasma Therapy in the Treatment of Androgenic Alopecia

Fractional Laser Versus Radiofrequency in Androgenetic Alopecia